Table 3 KIR and HLA gene frequencies, KIR haplotypes, and KIR-HLA ligand combinations in 135 advanced-stage classic Hodgkin lymphoma patients according to positive or negative interim PET-2 results

Activating KIR

 KIR2DS1

23

69.7

49

48.0

 KIR2DS2

27

81.8

51

50.0

0.001

4.5 (1.6–13.3)

 KIR2DS3

16

48.5

38

37.3

 KIR2DS4

28

84.9

96

94.1

 KIR2DS5

9

27.3

33

32.3

 KIR3DS1

16

48.5

37

36.3

Inhibitory KIR

 KIR2DL1

33

100

99

97.1

 KIR2DL2

22

66.7

58

56.9

 KIR2DL3

30

90.9

93

91.2

 KIR2DL4

33

100

102

100

 KIR2DL5

20

60.6

58

56.9

 KIR3DL1

33

100

102

100

 KIR3DL2

33

100

102

100

 KIR3DL3

33

100

102

100

KIR genotypes

 AA

5

15.2

37

36.3

0.03

0.31 (0.1–0.95)

 Bx

28

84.8

65

63.7

KIR ligands

 C1 pres

22

66.7

74

72.5

 C2 pres

27

81.8

88

86.3

 HLA-Bw4 pres

24

72.7

66

64.7

Activating KIR and their ligands

 KIR2DS1 pres/HLA-C2 pres

22

66.7

36

35.3

0.03

7.94 (0.496–173)

 KIR2DS1 pres/HLA-C2 abs

1

3.3

13

12.7

 KIR2DS2 pres/HLA-C1 pres

21

63.3

21

20.6

0.004

5.0 (1.55–16.8)

 KIR2DS2 pres/HLA-C1 abs

6

18.2

30

29.4

 KIR3DS1 pres/HLA-Bw4 pres

11

33.3

17

16.7

 KIR3DS1 pres/HLA-Bw4 abs

5

15.6

20

19.6

Inhibitory KIR and their ligands

 KIR2DL1 pres/HLA-C2 pres

27

81.8

59

57.8

0.021

3.05 (1.07–9.11)

 KIR2DL1 pres/HLA-C2 abs

6

18.2

40

42.2

 KIR2DL2 pres/HLA-C1 pres

19

62.7

33

32.3

0.018

4.8 (1.2–23.1)

 KIR2DL2 pres/HLA-C1 abs

3

9.1

25

24.5

 KIR2DL3 pres/HLA-C1 pres

23

69.7

55

53.9

 KIR2DL3 pres/HLA-C1 abs

7

21.2

38

37.3

 KIR3DL1 pres/HLA-Bw4 pres

22

66.7

65

63.7

 KIR3DL1 pres/HLA-Bw4 abs

11

33.3

37

36.3